Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,303.10 +8.60 0.06%
S&P 500 1,649.60 -0.91 -0.06%
Nasdaq 3,459.14 -0.27 -0.01%
Ticker Volume Price Price Delta
STOXX 50 2,764.29 -12.49 -0.45%
FTSE 100 6,654.34 -42.45 -0.63%
DAX 8,305.32 -46.66 -0.56%
Ticker Volume Price Price Delta
Nikkei 14,612.50 +128.47 0.89%
Hang Seng 22,618.70 -51.01 -0.23%
S&P/ASX 200 4,983.50 -78.95 -1.56%
  • Fund Type: SICAV
  • Objective: Sector Fund-Health & Biotech
  • Asset Class: Equity
  • Geographic Focus: Global

Credit Suisse SICAV Lux Equity Biotechnology

+ Add to Watchlist

CR4A:GR

195.3300 EUR 0.2700 0.14%

As of 14:55:53 ET on 05/24/2013.

Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Snapshot for Credit Suisse SICAV Lux Equity Biotechnology (CR4A)

Open: 195.0700 High - Low: 195.3900 - 192.6100 Primary Exchange: Berlin
Volume: 0 52-Week Range: 134.2500 - 204.0800 Beta vs NBI: 0.8053

ETF Chart for CR4A

No chart data available.
  • CR4A:GR 193.8960
  • 1D
  • 1M
  • 1Y
195.6000
Interactive CR4A Chart

Previous Close

Fund Profile & Information for CR4A

Credit Suisse SICAV (Lux) Equity Biotechnology is a SICAV incorporated in Luxembourg. The Fund's objective is long-term capital growth. The Fund invests in a portfolio of equity securities of biotechnology companies worldwide.

Inception Date: 2001-11-06 Telephone: -
Managers: IRENE B PUTTNER
Web Site: www.credit-suisse.com

Fundamentals for CR4A

NAV -
Assets (M) (on 2013-05-23) 169.3177
Shares out (M) 0.00
Market Cap (M) 0.00
% Premium -
Average 52-Week % Premium -
Fund Leveraged N

Dividends for CR4A

No dividends reported

Performance for CR4A

1-Month +5.46% 1-Year +38.01%
3-Month +24.00% 3-Year +26.65%
Year To Date +32.65% 5-Year +8.85%
Expense Ratio -

Top Fund Holdings for CR4A

Filing Date: 03/27/2013
Name Position Value % of Total
Gilead Sciences Inc 260,484 12,430,296 8.108%
Celgene Corp 107,638 12,188,927 7.951%
Biogen Idec Inc 52,745 9,635,457 6.285%
Amgen Inc 84,973 8,510,046 5.551%
BioMarin Pharmaceutical Inc 130,444 7,873,600 5.136%
Vertex Pharmaceuticals Inc 141,000 7,731,030 5.043%
Onyx Pharmaceuticals Inc 85,000 7,525,050 4.908%
Regeneron Pharmaceuticals Inc 44,000 7,519,600 4.905%
Alexion Pharmaceuticals Inc 74,752 7,020,708 4.580%
Incyte Corp Ltd 265,000 6,007,550 3.919%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Financial Commentaries

Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil